Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS
The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this Notice to Modala Bio, Inc. (Modala), headquartered in Delaware.
Related coverage
- Investment Company Cross Trading
- Privacy Act of 1974; Systems of Records
- Premium Tax Credit
- Taking and Importing Marine Mammals; Taking Marine Mammals Incidental to Russian River Estuary Management Activities
- Amendment to Memorandum Describing the Authority and Assigned Responsibilities of the General Counsel of the Federal Labor Relations Authority
- Meaning of Terms as Used in This Subchapter; Representation Proceedings; National Consultation Rights and Consultation Rights on Government-Wide Rules or Regulations; Miscellaneous and General Requirements